TickerFacts.

GeneDx Holdings Corp. (WGS): R&D Expense

Annual figures by period end, from SEC filings.

$72.03M
Year ended 2025-12-31
$83.83M
Trailing 12 months to 2026-06-30
-5.8%
3-year compound annual growth
-0.2%
5-year compound annual growth
$105.16M2019-12-31: $34.91M2020-12-31: $72.70M2021-12-31: $105.16M2022-12-31: $86.20M2023-12-31: $58.27M2024-12-31: $45.72M2025-12-31: $72.03M$72.03M
2019-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$72.03M+57.5%2026-02-23, From 2025-01-01
2024-12-31$45.72M-21.5%2026-02-23, From 2024-01-01
2023-12-31$58.27M-32.4%2026-02-23, From 2023-01-01
2022-12-31$86.20M-18.0%2024-02-23, From 2022-01-01
2021-12-31$105.16M+44.7%2023-03-16, From 2021-01-01
2020-12-31$72.70M+108.2%2023-03-16, From 2020-01-01
2019-12-31$34.91Mn/a2022-03-14, From 2019-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Health Services), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
GeneDx Holdings Corp. (WGS)2025-12-31$72.03M+57.5%
DocGo Inc. (DCGO)2025-12-31$13.56M+17.0%
Omada Health, Inc. (OMDA)2025-12-31$40.68M+13.3%
EUDA Health Holdings Ltd (EUDA)2025-12-31$249n/a

Compare WGS, DCGO, OMDA, EUDA side by side · Screen every company in Services-Health Services ↗